Dabixta75 mg

Dabixta is a direct thrombin inhibitor (an oral anticoagulant) used to reduce the risk of blood clots and stroke. Its uses can be classified by strength of evidence as follows:

FDA-approved (established) indications

• Stroke and systemic embolism prevention in non-valvular atrial fibrillation (NVAF) — to reduce the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation.
• Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) — in adult patients who have been treated with a parenteral (injectable) anticoagulant for 5 to 10 days.
• Reduction in the risk of recurrence of DVT and PE — in adult patients who have previously received treatment.
• Treatment of venous thromboembolism (VTE) and reduction in risk of VTE recurrence in pediatric patients — in appropriate age groups, after at least 5 days of initial parenteral anticoagulation (see Pediatric Uses).

Guideline-supported / internationally approved uses

• Primary prevention of venous thromboembolism after major orthopedic surgery (e.g., elective hip or knee replacement surgery) — this indication is approved and guideline-supported in several countries outside the United States, though it is not a US FDA-labeled indication for Dabixta.

Note: Dabixta is not indicated for patients with mechanical prosthetic heart valves (see Contraindications), and is not used as an antiplatelet agent for acute coronary syndromes.

Dabigatran Etexilate Mesylate oral capsules are available in different strengths (commonly 75 mg, 110 mg, and 150 mg, depending on market and indication), each containing dabigatran etexilate in the mesylate salt form, equivalent to the labeled strength of dabigatran etexilate. Inactive ingredients typically include tartaric acid core pellets, gum arabic, hypromellose, dimethicone, talc, and a capsule shell with printing ink; exact excipients vary by manufacturer.

Dabixta is the pharmaceutical salt form of dabigatran etexilate, an orally administered prodrug that is rapidly converted by esterases in the body to dabigatran, the active moiety. Dabigatran is a potent, reversible, direct inhibitor of thrombin (both free and clot-bound thrombin), which is the central enzyme in the coagulation cascade responsible for converting fibrinogen into fibrin.

Dabixta belongs to the class of medicines known as direct oral anticoagulants (DOACs) and offers an alternative to vitamin K antagonists (such as warfarin) for long-term anticoagulation, without requiring routine coagulation monitoring under most circumstances.

Direct Thrombin Inhibitor (Oral Anticoagulant) — Dabixta is classified as a Direct-Acting Oral Anticoagulant (DOAC).

Mechanism

Dabigatran Etexilate Mesylate is hydrolyzed after oral absorption (by esterase-catalyzed hydrolysis) to form dabigatran, its active form. Dabigatran directly and reversibly inhibits thrombin (factor IIa), preventing the conversion of fibrinogen to fibrin and thereby preventing clot formation. It also inhibits free and clot-bound thrombin and thrombin-induced platelet aggregation.

Pharmacokinetics

• Absorption: Oral bioavailability of dabigatran from Dabigatran Etexilate Mesylate is low (approximately 3-7%); it is a substrate of the P-glycoprotein (P-gp) efflux transporter.
• Distribution: Plasma protein binding is low (approximately 35%).
• Metabolism: Dabigatran is conjugated to form acylglucuronides; it is not metabolized by cytochrome P450 enzymes.
• Elimination: Approximately 80% of the dose is excreted unchanged by the kidneys, making renal function a critical determinant of drug exposure. Elimination half-life is approximately 12-17 hours in patients with normal renal function and is prolonged in renal impairment.

• Dabixta capsules should be swallowed whole with a full glass of water; do not break, chew, crush, or open the capsule and sprinkle the contents on food or in liquid, as this significantly increases the rate of absorption and bleeding risk.
• May be taken with or without food.
• If a dose is missed, it should be taken as soon as possible on the same day; a missed dose should not be taken if it is close to the time of the next scheduled dose, and doses should never be doubled.
• Do not discontinue Dabixta without consulting the prescribing physician, as premature discontinuation increases the risk of thrombotic events (see Precautions and Warnings).
• Dispense and store in the original manufacturer's container/bottle; do not transfer to pill organizers or boxes (see Storage Conditions).

Dabixta is a substrate of the P-glycoprotein (P-gp) efflux transporter, so drugs that affect P-gp activity can significantly alter dabigatran blood levels and clinical risk.

• P-gp inhibitors (e.g., ketoconazole, dronedarone, verapamil, amiodarone, clarithromycin, ritonavir): can substantially increase dabigatran exposure, raising bleeding risk. Some combinations require dose reduction, monitoring, or avoidance, especially in patients with reduced renal function.
• P-gp inducers (e.g., rifampin, St. John's Wort, carbamazepine, phenytoin): can substantially decrease dabigatran exposure, reducing anticoagulant effect and increasing thrombotic risk; concomitant use should generally be avoided.
• Other anticoagulants, antiplatelet agents, and thrombolytics (e.g., heparin, warfarin, aspirin, clopidogrel, NSAIDs, SSRIs/SNRIs): concurrent use increases bleeding risk and should only be undertaken with close medical supervision.
• Idarucizumab is a specific reversal agent for dabigatran and may be used by physicians in emergency bleeding or urgent surgical situations (see Overdose).

Patients should inform their physician of all prescription medicines, over-the-counter drugs, and herbal supplements they are taking before starting Dabixta.

The most common adverse effects of Dabixta relate to bleeding and gastrointestinal tolerability.

Common side effects

• Dyspepsia (indigestion, upper abdominal discomfort), gastritis-like symptoms, and abdominal pain.
• Bleeding events of varying severity, including epistaxis (nosebleeds), gastrointestinal bleeding, bruising, and hematuria (blood in urine).
• Nausea.

Serious side effects (seek urgent medical attention)

• Major or life-threatening bleeding (e.g., severe gastrointestinal bleeding, intracranial hemorrhage) — signs include unusual bruising, pink/brown urine, red/black stools, coughing up blood, or severe unexplained weakness.
• Signs of spinal or epidural hematoma in patients undergoing spinal procedures (see Precautions and Warnings).
• Signs of hypersensitivity/anaphylaxis (rash, swelling of face/throat, difficulty breathing).

Pregnancy

Data on the use of Dabixta in pregnant women are limited. Dabixta should be used during pregnancy only if the potential benefit to the mother clearly justifies the potential risk to the fetus, and only under close physician supervision. Patients who become pregnant while taking Dabixta should contact their physician promptly to discuss alternative anticoagulation options, as most guidelines favor other anticoagulants (e.g., heparins) during pregnancy.

Lactation

It is not well established whether dabigatran passes into human breast milk in clinically significant amounts. Because of the potential for serious adverse reactions (including bleeding) in a nursing infant, a decision should be made whether to discontinue breastfeeding or discontinue Dabixta, taking into account the importance of the drug to the mother — this decision should be made in consultation with a physician.

Boxed warnings

• Spinal/epidural hematoma: Patients receiving Dabixta who undergo neuraxial anesthesia (spinal/epidural) or spinal puncture are at risk of developing an epidural or spinal hematoma, which can result in long-term or permanent paralysis. Risk is increased with indwelling epidural catheters, concomitant use of other drugs affecting hemostasis, and traumatic or repeated punctures.
• Premature discontinuation increases thrombotic risk: Discontinuing Dabixta without adequate alternative anticoagulation increases the risk of thrombotic events, including stroke. If therapy must be discontinued for a reason other than pathological bleeding, an alternative anticoagulant should be considered.
• Mechanical heart valves: Dabixta is contraindicated in patients with mechanical prosthetic heart valves due to increased risk of thrombotic and bleeding events compared with warfarin (see Contraindications).

Other precautions

• Renal impairment: Because Dabixta is substantially cleared by the kidneys, dose adjustment or avoidance is required based on creatinine clearance (see Dosage and Administration). Renal function should be assessed before and periodically during treatment.
• Bleeding risk: Dabixta increases the risk of bleeding and can cause serious, potentially fatal hemorrhage. Use with caution in patients with conditions that increase bleeding risk (e.g., recent surgery, active peptic ulcer disease, congenital or acquired bleeding disorders).
• Drug interactions: Concomitant P-gp inhibitors or inducers can significantly affect drug levels (see Interaction).
• Emergency reversal: A specific reversal agent, idarucizumab, is available for use by physicians when rapid reversal of the anticoagulant effect of Dabixta is needed for emergency surgery or life-threatening/uncontrolled bleeding.

Overdose of Dabixta increases the risk of bleeding complications. Signs of overdose may include unusual bruising, blood in urine or stool, prolonged bleeding from cuts, severe headache, dizziness, or weakness.

Any suspected overdose of Dabixta is a medical emergency — the patient or caregiver should seek immediate medical attention or contact emergency services/poison control without delay. There is a specific reversal agent (idarucizumab) that a physician may administer in a hospital setting for serious bleeding or when urgent reversal of anticoagulation is required. Management may also include supportive care and, in select cases, hemodialysis (as dabigatran is dialyzable) at the discretion of the treating physician. Do not attempt to manage a suspected overdose at home.

Store Dabixta capsules at room temperature (below 30°C), protected from light and moisture. Keep the capsules in their original manufacturer container/blister and do not repackage into pill organizers or boxes, as the medicine is sensitive to moisture. Once a bottle is opened, use within the period specified by the manufacturer (commonly around 4 months) and discard any unused capsules thereafter. Keep out of reach of children.

• Renal impairment: Dose adjustment is required for moderate renal impairment in NVAF; Dabixta is not recommended in severe renal impairment or dialysis-dependent patients (see Dosage and Administration).
• Hepatic impairment: Dabixta has not been extensively studied in patients with severe hepatic impairment or liver disease associated with coagulopathy; such patients were excluded from major clinical trials, so use is not recommended in this population.
• Elderly patients: Elderly patients (particularly those over 75 years) have a higher risk of bleeding and often reduced renal function; closer monitoring is advised, though routine dose reduction based on age alone is not required outside the renal-based adjustments above.
• Body weight: Very low body weight (e.g., <50 kg) may be associated with increased drug exposure; use with caution and monitor for bleeding.
• Pediatric patients: See Pediatric Uses.

Duration of Dabixta therapy depends on the indication and individual risk-benefit assessment:

• Non-valvular atrial fibrillation: Typically long-term or indefinite therapy, as stroke risk persists as long as the underlying arrhythmia and risk factors are present; continued only under regular physician review.
• Treatment of DVT/PE: Usually at least 3 months, following an initial 5-10 days of parenteral anticoagulation; duration may be extended based on the presence of ongoing risk factors.
• Reduction in risk of recurrent DVT/PE: May be continued for extended periods in patients at high risk of recurrence, per physician assessment.

Patients should never stop Dabixta abruptly without physician guidance (see Precautions and Warnings).

Anticoagulants > Direct Thrombin Inhibitors > Direct Oral Anticoagulants (DOACs)

Dabigatran Etexilate Mesylate is metabolized to dabigatran, which acts as a competitive, reversible, direct inhibitor of thrombin (coagulation factor IIa). By binding directly to the active site of thrombin, dabigatran blocks the thrombin-mediated conversion of fibrinogen to fibrin, a critical step in clot formation. It inhibits both free thrombin and clot-bound thrombin, as well as thrombin-induced platelet aggregation, thereby reducing the propagation of existing clots and preventing new clot formation without requiring antithrombin as a cofactor (unlike heparin).

C

Dabixta has an established pediatric indication for the treatment of venous thromboembolism (VTE) and reduction in the risk of VTE recurrence in pediatric patients, following at least 5 days of initial treatment with a parenteral anticoagulant. Age-appropriate formulations (e.g., oral pellets for younger children, capsules for older children/adolescents) and weight-based, age-based dosing regimens established in pediatric clinical trials should be used, and dosing must be individualized by a pediatric specialist familiar with the specific dosing tables.

Safety and efficacy of Dabixta for stroke prevention in non-valvular atrial fibrillation have not been established in pediatric patients, as this condition is rare in children. Dabixta should only be used in children under close specialist supervision.